Synbiotic Treatment in Crohn's Disease Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00305409|
Recruitment Status : Completed
First Posted : March 21, 2006
Last Update Posted : February 11, 2009
|Condition or disease||Intervention/treatment|
|Crohn's Disease||Drug: Synbiotic (Synergy I / B.longum)|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Synbiotic Treatment in Crohn's Disease Patients|
|Study Start Date :||June 2006|
|Primary Completion Date :||December 2008|
|Study Completion Date :||December 2008|
- Reduction in mucosal TNF-alpha
- Number of patients in remission as assessed by CDAI.
- Significant differences in mucosal regeneration between pre-synbiotic and post-synbiotic therapy groups and pre-control and post-control therapy groups.
- Differences in TNF-alpha, IL-18 and INF-gamma between the post-synbiotic and post-control groups.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00305409
|Dundee University, Dept of Pathology and Neuroscience|
|Dundee, Angus, United Kingdom, DD1 9SY|
|Ninewells Hospital and Medical School|
|Dundee, Tayside, United Kingdom, DD1 9SY|
|Principal Investigator:||George MacFarlane, BSc PhD||University of Dundee|